Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

NCT04752540 is registered in ClinicalTrials.gov with F2G Biotech GmbH as lead sponsor.

NCT NCT04752540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Lead sponsor
F2G Biotech GmbH
Phase
Phase 1
Overall status
Completed
Start date
July 2, 2021
Completion date
October 24, 2021
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment